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Abstract
Background
High mortality rates have been reported in patients with cerebral venous sinus thrombosis (CVST) 
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adenoviral vector SARS-CoV-2 vaccines. The aim of this study was to evaluate whether mortality 
of patients with CVST-VITT has decreased over time. 
Methods
We used the EudraVigilance database of the European Medicines Agency to identify cases of 
CVST with concomitant thrombocytopenia occurring within 28 days of SARS-CoV-2 vaccination. 
Vaccines were grouped based on vaccine type (adenoviral or mRNA). Cases with CVST onset 
until 28 March were compared to cases after 28 March 2021, which was the day when the first 
scientific paper on VITT was published.
Results
We identified 270 cases of CVST with thrombocytopenia, of which 266 (99%) occurred after 
adenoviral vector SARS-CoV-2 vaccination (ChAdOx1 nCoV-19 n=243, Ad26.COV2.S n=23). 
Reported mortality among adenoviral cases with onset up to 28 March 2021 was 47/99 (47%, 
95%CI 37–58%) compared to 36/167 (22%, 95%CI 16–29%) in cases with onset after 28 March 
(p=<0.001). None of the 4 cases of CVST with thrombocytopenia occurring after mRNA 
vaccination died.
Conclusion
Reported mortality of CVST with thrombocytopenia after vaccination with adenoviral vector-
based SARS-CoV-2 vaccines has significantly decreased over time, which may indicate a 
beneficial effect of earlier recognition and/or improved treatment on outcome after VITT.
Introduction
Since March 2021, cases of cerebral venous sinus thrombosis (CVST) with thrombocytopenia 
after vaccination with the adenovirus-based SARS-CoV-2 vaccines ChAdOx1 nCoV-19 
(Vaxzevria, AstraZeneca/Oxford) and Ad26.COV2.S (Janssen/Johnson&Johnson) have been 
reported (vaccine-induced immune thrombotic thrombocytopenia [VITT]).1-6 Early reported 
mortality rates among patients with VITT, especially in those with CVST, were high, ranging 
between 30 and 60%.1-4 After the discovery that the underlying pathophysiology of anti-platelet 
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induced thrombocytopenia (HIT), specific treatment recommendations that differ from standard 
CVST care were proposed, based on the following three pillars: 1. use of non-heparin based 
anticoagulants, 2. use of immunomodulation, with intravenous immunoglobulin as 1st line 
treatment, and 3. avoidance of platelet transfusion.1,7
Now that VITT is a recognized side effect, and treatment recommendations are in place which are 
widely endorsed by international organizations,8,9 the question arises whether outcome of patients 
with CVST-VITT has improved over time. In an attempt to answer this question, we compared 
acute mortality rates from the EudraVigilance database of the European Medicines Agency (EMA) 
in two different time periods.
Methods
Data selection
This is an extension of a previously published study which also used EudraVigilance data, and 
where the methods are described in more detail.4 Briefly, EudraVigilance is a passive 
pharmacovigilance system hosted and maintained by EMA in which suspected adverse drug 
reactions (ADRs) are collected from countries inside and outside the European Economic Area 
(EEA). Marketing authorization holders and national competent authorities are obliged to report 
any suspected ADRs occurring within the EEA as well as any suspected serious ADRs occurring 
within and outside the EEA.10 The authors were granted level 2A access to Medical Dictionary for 
Regulatory Activities High Level Group Term (MedDRA HLGT, version 24.0) ‘Central nervous 
system vascular disorders’.11 For the current study, data on all suspected adverse events reported 
to EudraVigilance until 13 June 2021 for the four available SARS-CoV-2 vaccines approved 
through EMA were extracted.
We identified all cases of CVST with reported concomitant thrombocytopenia and symptom onset 
within 28 days after vaccination with one of the adenoviral vector-based SARS-CoV-2 vaccines 
approved by EMA (ChAdOx1 nCov-19 and Ad26.COV2.S). For comparison, we collected cases 
after mRNA-based SARS-CoV-2 vaccines (BNT162b2 and mRNA-1273). We assumed CVST 
with reported concomitant thrombocytopenia to be CVST-VITT, as thrombocytopenia has been 
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with “Preferred Terms” (PTs) of the Medical Dictionary for Regulatory Activities (MedDRA) 
were screened by two authors (AM and KK) for PTs corresponding with CVST and potential 
CVST (Supplemental Table 1). Cases marked as “suspected CVST” after screening were 
adjudicated by a senior vascular neurologist (JMC). Cases were marked as having concomitant 
thrombocytopenia if a PT related to thrombocytopenia was reported (Supplemental Table 1), or if 
they had a reported platelet count of <150 x109/L (Supplemental Table 2). For the analysis, the 
adenovirus vector-based vaccines were grouped together, as were the mRNA vaccines. Because of 
a potential delay between CVST onset and death, all cases with CVST onset after 30 May 2021 
were excluded from the analysis.
As a baseline characteristic, we screened the adenoviral vector vaccine group for adverse reactions 
coded with PTs related to intracranial hemorrhage (Supplemental Table 1). Only intracranial 
hemorrhages with a reported onset date prior to or equal to the CVST onset date were included. In 
addition, we screened the adenoviral vector vaccine group for cases with any confirmed COVID-
19 infection (Supplemental Table 1 and 2).
Data analysis
To evaluate a shift in mortality over time, cases with CVST onset up to and including 28 March 
were compared to those with onset after 28 March 2021. This cut-off date was selected because on 
that day the first paper on VITT, which included treatment recommendations, was published on a 
preprint server, receiving worldwide attention both among physicians and in the media.1,13
We calculated medians and interquartile ranges for continuous variables, and counts and 
percentages for categorical variables. We calculated 95% confidence intervals (95%CI) using the 
Clopper-Pearson Exact method for mortality rates. A Chi-square test was performed to compare 
mortality of CVST between the two time periods. We performed a sensitivity analysis restricted to 
subjects within the EEA and United Kingdom (UK) because of a potential reporting bias by non-
EEA countries, which initiated reporting of cases at a later stage. Analyses were performed with 
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Results
Among 8,537 individual cases with at least one reaction in the MedDRA HLGT ‘Central nervous 
system vascular disorders’, we identified 270 cases of CVST with thrombocytopenia within 28 
days of SARS-CoV-2 vaccination (Figure 1). Of these, 266 (99%) occurred after vaccination with 
an adenoviral vector-based vaccine (ChAdOx1 nCov-19 n=243, Ad26.COV2.S, n=23). Only 
3/243 cases occurred after a second vaccination with ChAdOx1 nCov-19. Group characteristics 
are shown in Table 1.
Overall mortality was 83/270 (31%, 95%CI 25-37%). In the adenoviral vector vaccine group, 
mortality was 83/266 (31%, 95%CI 26–37%). Mortality after ChAdOx1 nCov-19 vaccination was 
79/243 (33%, 95%CI 27-39%) and after Ad26.COV2.S vaccination 4/23 (17%, 95%CI 5-39%). In 
the adenoviral vector vaccine group with onset until 28 March, mortality was 47/99 (47%, 95%CI 
37–58%) compared to 36/167 (22%, 95%CI 16–29%) in cases with CVST onset after 28 March 
(p=<0.001). No fatalities were reported in the mRNA vaccine group (n=4).
In the sensitivity analysis using only cases from the EEA and UK, mortality rates were comparable 
to the mortality rates when including all countries with 45/95 (47%, 95%CI 37-58%) in cases with 
onset until 28 March compared to 34/147 (23%, 95%CI 17-31%) in cases with CVST onset after 
28 March.
Discussion
We found that the reported mortality of CVST with thrombocytopenia after vaccination with 
adenoviral vector SARS-CoV-2 vaccines has fallen substantially, from 47% to 22% in cases with 
symptom onset before and after 28 March 2021, respectively. This decrease in mortality could be 
the result of earlier diagnosis and/or improved treatment, but this cannot be ascertained with 










This article is protected by copyright. All rights reserved
CVST-VITT is available,8 intravenous immunoglobulins have been found to raise platelet counts 
and decrease hypercoagulability in patients with autoimmune HIT.1 
Other potential explanations for the decrease in mortality should be taken into account. First, 
increased awareness of VITT among physicians after 28 March may have resulted in the 
identification and subsequent reporting of less severe cases. Although sex, age and baseline 
intracranial hemorrhage were relatively similar in both time periods, no other detailed information, 
for instance on baseline characteristics, co-morbidities, and markers of CVST severity, is available 
with level 2A access to EudraVigilance. Second, the population that received vaccination may 
have shifted over time. For instance, most countries prioritized vaccination for those most at risk 
of severe disease14, such as older people and people with underlying health conditions, and these 
people could have a higher risk of death after VITT. Third, mortality can theoretically have been 
higher in the earlier cases because of a longer follow-up time. Unfortunately, date of death is not 
systematically recorded in EudraVigilance. However, since the mortality rate in the earlier cases is 
similar to our previous analysis which contained EudraVigilance data until 8 April 2021 (mortality 
rate 49%),4 the longer follow-up duration is an unlikely explanation for the observed difference in 
mortality. 
As previously reported,4 the most important limitation of the study is the quality and completeness 
of the EudraVigilance database. Because EudraVigilance is a passive pharmacovigilance system, a 
risk of underreporting is present, especially for less severe cases. Data were not centrally 
validated, and thus the accuracy and completeness of the reported information is unknown. 
Because marketing authorization holders and national competent authorities can only report ADRs 
that they are aware of, a risk of selective reporting remains present. In addition, some patients with 
CVST-VITT prior to 28 March 2021 likely remained undiagnosed, because VITT was an 
unknown condition at that time. Acute death caused by CVST-VITT could have been 
misclassified, potentially resulting in an underestimation of the reported mortality rate before 28 
March. The numbers of CVST cases after Ad26.COV2.S vaccination were limited, making it 










This article is protected by copyright. All rights reserved
In summary, reported mortality of CVST with thrombocytopenia after vaccination with adenoviral 
vector-based SARS-CoV-2 vaccines decreased over time, which could indicate a beneficial effect 
of earlier diagnosis and/or treatment recommendations for VITT on patient outcome. 
Nevertheless, even after 28 March, reported mortality rates remained high, especially in 
comparison with mortality rates of CVST patients prior to the COVID-19 pandemic.4,15
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Figure Legends
Figure 1. Flowchart of case selection. CVST = cerebral venous sinus thrombosis; MedDRA 
HLGT = Medical Dictionary for Regulatory Activities High Level Group Term.
Tables
Table 1. Characteristics of cerebral venous sinus thrombosis (CVST) cases with 
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 Patients with CVST after adenoviral 
vector vaccination 
N = 266 
 Until 28 March 
N = 99 
After 28 March 
N = 167 





Female sex, n/N (%) 83/99 (84) 108/167 (65) 









1/99 (1) 2/167 (1) 
Lowest reported platelet 








   




COVID-19 = Coronavirus Disease 2019; CVST = cerebral venous sinus thrombosis; IQR = 
interquartile range. 
§ Missing cases (N = 43) had an intracranial hemorrhage with an unknown onset date. ¶ One 
patient had a COVID-19 infection prior to CVST onset, the date of COVID-19 infection onset 
was unknown in the other two patients. 
Number of missing values: †18; ‡29; ††17; ‡‡46 
* p = < 0.001 
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